News and Comments: Have Phase Ⅲ clinical trials of Compound Danshen Dripping Pill “tragically failed”?
Journal Title: Traditional Medicine Research - Year 2018, Vol 2, Issue 4
Abstract
Compound Danshen Dripping Pill (CDDP) is the traditional Chinese medicine that has been widely used in China for the treatment of diseases such as coronary heart disease, stenocardia, and myocardial ischemia. The application of the pills was submitted to the USA Food and Drug Administration (FDA) in 1997. It was also the first TCM to enter phase III clinical trials by the FDA. However, news about the failure of the phase III clinical trials of CDDP was recently reported.
Authors and Affiliations
Cui-Hong Zhu, Xiong-Zhi Wu，Editor Group of TMR
Keywords
Related Articles
- EP ID EP45248
- DOI -
- Views 258
- Downloads 0
Cooking activity for patients with Alzheimer’s disease: a review
As a degenerative nervous system disease, Alzheimer’s disease (AD), can damage memory and cognitive function.Cooking activity, aninstrumental activity of daily life, is one of the non-pharmacological therapies with posit...
Astragalus injection as an adjuvant treatment for colorectal cancer: a meta-analysis
Background: The combination of Chinese patent medicine Astragalus injection and Western medicine has achieved a certain clinical effect in colorectal cancer patients. However, due to the uneven basic conditions and resea...
Qiming granule in treating type 2 diabetic kidney disease patients: study protocol for a randomized controlled trial
Background: Diabetic kidney disease (DKD) is a chronic renal microvascular complication associated with abnormal glucose metabolism. According to traditional Chinese medicine (TCM) theory, Qi and Yin deficiency with bloo...
Treating COVID-19 by traditional Chinese medicine: a charming strategy?
On April 14, 2020, the State Council of China announced that “three proprietary Chinese medicines and three decoctions” of effective traditional Chinese medicine (TCM) in the treatment of the novel coronavirus pneumonia...
News and comments: Do aristolochic acids truly increase the occurrence of hepatocellular carcinoma?
Recently, Science Translational Medicine pointed out that 78% of the 98 hepatocellular carcinoma (HCC) samples from Taiwan, China, showed distinctive signatures of aristolochic acids (AAs) exposure. In addition, 47% of t...